Team:UIUC-Illinois/Team/Advisors
From 2012.igem.org
(Difference between revisions)
Line 171: | Line 171: | ||
<li>Entrepreneurship (New Venture Creation) Theory Strategy</li> | <li>Entrepreneurship (New Venture Creation) Theory Strategy</li> | ||
</ul> | </ul> | ||
+ | <br/> | ||
+ | <a href="https://netfiles.uiuc.edu/jabradly/www/">Click here for more information about this advisor.</a> | ||
</p> | </p> | ||
</td> | </td> | ||
Line 184: | Line 186: | ||
<td width="790" valign="top" align="left"> | <td width="790" valign="top" align="left"> | ||
<p><center><font size="6">Dr. Zefeng Wang</font></p> | <p><center><font size="6">Dr. Zefeng Wang</font></p> | ||
- | < | + | <br/> |
+ | Department of Pharmacology, University of North Carolina at Chapel Hill<br/><br/> | ||
+ | |||
+ | Research Interests: | ||
+ | <ul><li> | ||
+ | Identify splicing regulatory cis-elements and trans-factors (compiling the splicing code)</li> | ||
+ | <li>Develop new method to modulate splicing (debugging the splicing code)</li> | ||
+ | </ul> | ||
+ | <br/> | ||
+ | |||
+ | <a href="http://www.med.unc.edu/pharm/people/primaryfaculty/zefeng-wang/wang">Click here to learn more about this advisor.</a> | ||
</td> | </td> | ||
</tr> | </tr> |
Revision as of 03:40, 26 October 2012